Abstract: Provided herein are compounds that inhibit IDO1 and methods of use thereof. Also provided are pharmaceutical compositions and medicaments that include the compounds described herein as well as methods of treating sarcopenia or age-related muscle loss.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: The disclosure relates to N-methyl-N-allyl-tryptamine (MALT) hydrofumarate, crystalline MALT hydrofumarate, N—N-dibutyl-tryptamine (DBT) iodide, crystalline DBT iodide, crystalline N-ethyl-N-propyl-tryptamine (EPT) hydrofumarate, and crystalline N—N-diisopropyl-tryptamine (DiPT) hydrofumarate, compositions containing them, and the methods of treatment using them.

Abstract: The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near-infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.

Abstract: One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.

Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

Abstract: The present disclosure relates to a dermal drug delivery platform comprising: a primary wound dressing comprising three-dimensional polymer protuberances that extend upward from the dressing surface to engage the wound. The protuberances comprise at least one biocompatible and/or biodegradable polymer and medicinal nanoparticles. In one embodiment, the medicinal nanoparticles may be metallic and provide surface-area-enhanced galvanic action to drive medicinal ions into the wound bed. Various methods of making the disclosed dermal drug delivery platform, as well as three-dimensional methods of treating a wound using the platform are also disclosed.

Abstract: A syringe adapter is provided. The adapter includes a housing having a first end and a second end positioned opposite the first end. The first end of the housing has a connector configured to be secured to a syringe barrel. The adapter also includes a cannula positioned within the housing and a seal arrangement including a membrane or septum positioned within the housing and movable within the housing, the seal arrangement comprising a membrane. The assembly can also include a protective cap having a first open end and a second closed end. The protective cap can be connected to the housing via a snap fit and can be configured to receive the second end of the housing.

Abstract: A device for establishing venous inflow to a blood reservoir of an extracorporeal blood circulation system includes a restricting unit for gradually closing a venous inflow line and a vacuum unit for supplying vacuum to the blood reservoir. The device includes a control unit that supplies a first actuating signal to the restricting unit for restricting venous inflow to the blood reservoir and supplies a second actuating signal to the vacuum unit for establishing a degree of vacuum within the blood reservoir.

Abstract: The pyrazolidinedione derivatives were found to possess blood glucose lowering properties. These compounds were designed as potential PPAR gamma inhibitors, an essential molecular target for clinically used antidiabetic drugs. Owing to their promising anti-hyperglycemic activity, these derivatives may find useful applications for the treatment and/or prevention of obesity, diabetes type II and I, hyperglycemia and other diseases where PPAR gamma is implicated such as cancer, atherosclerosis and hyperlipidemia.

Abstract: A garment is provided to be worn post-surgery during recovery from urological surgical procedure. The garment is in the form of men's underwear or brief, with features provided to assist in recovery and comfort of the user. The garment includes a center flap that can be opened to provide access to a center pocket that is aligned with the user's crotch. The center pocket contains a moldable body that can be molded to a particular shape to support and hold the user's penis in a pre-determined orientation to facilitate the recovery process. The flap also includes a pocket that can contain a heating/cooling pack that is arranged to apply heat/cooling to the surgical site. The garment is also configured to accept and support a medical drainage tube to drain the surgical wound, and a drainage pump as needed.

Abstract: Disclosed is an array 1 of wearable articles 20, each article comprising a main body 38 and a ring-like elastic belt 40 comprising a front belt and a back belt wherein at least the front belt or the back belt is an elastic member having an elastic member width in the transverse direction and a non-elastic region; wherein a first elastic member of a first article comprises a first non-elastic region; a second elastic member of a second article comprises a second non-elastic region; a third elastic member of a third article comprises a third non-elastic region; wherein the elastic member width of the first, second, and third elastic members are the same; and the first, second, and third non-elastic regions are different from each other.

Abstract: A crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having peaks at diffraction angles 2?)(° of 12.6±0.2, 16.0±0.2, 17.7±0.2, 18.5±0.2, and 21.3±0.2 in powder X-ray diffraction; and the crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperi din-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having an endothermic peak at 173° C. to 177° C. in simultaneous thermogravimetric-differential thermal analysis.

Abstract: An absorbent article includes a first waist region, a second waist region, and a crotch region disposed between the first and second waist regions. The article also includes a chassis having a topsheet, a backsheet, and an absorbent core disposed between the topsheet and backsheet; and an ear joined to the chassis. The ear includes a laminate formed from a first nonwoven and second nonwoven and an elastomeric material sandwiched between said first and second nonwovens. The laminate further includes a plurality of ultrasonic bonds.

Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: A filtering device for removing particles from a fluid of a patient is provided. The filtering device being implantable in the patient's body and comprising a cassette comprising a revolving member, said revolving member having at least two segments each holding a respective filter. The device further comprises a tube forming a fluid passageway through one of the filters in said cassette, wherein the cassette is adapted to, upon revolution of the revolving cylinder, change the filter positioned in the fluid passageway from a first one of said filters to a second one of said filters, thereby allowing particles present on the first filter to be moved away from the fluid passageway, while at the same time changing the filter positioned in the fluid passageway.

Abstract: Certain embodiments provide systems, methods, and computer program products that administer pain management treatments remotely, according to a dynamic prescription. In some embodiments, the dynamic prescription provides for changes in a dosage of a medication or electrical stimulation, based for instance upon changes in the patient's pain tolerance level, biological indicators, or behavioral characteristics. In some embodiments, if it is determined that a dosage change is needed, the dosage change can be compared against the dynamic prescription to determine whether the dosage change is permitted within the scope of the dynamic prescription. In some embodiments, if the dosage change is determined to be outside what is permitted by the scope of the dynamic prescription, the updated dosage information can be provided to the patient's physician for authorization of the updated dosage.

Abstract: Novel tetracyclic aza-podophyllotoxin analogue compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The tetracyclic aza-podophyllotoxin analogue compounds are useful as antitumor agents.

Abstract: A wound therapy device is disclosed. The wound therapy device may include a housing for covering at least a portion of a wound and for sealing to a body surface of a patient. The housing may also include a liquid collector for retaining liquid therein and a vacuum connection for coupling to a vacuum source. The vacuum connection may be in gaseous communication with the liquid collector. The vacuum connection may be separated from the liquid collector by a liquid barrier.